Mineralys Therapeutics, Inc. (MLYS) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $29.00: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor for uncontrolled/resistant hypertension and related cardiorenal conditions. An NDA was submitted December 2025 with a PDUFA date of December 22,... Read more
Sell if holding. Engine safety override at $29.00: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: RSI 58 mid-range, Bollinger mid-band. Score 5.1/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 5d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductlorundrostat10-K Item 1A: 'We currently depend entirely on the success of lorundrostat, which is our only product candidate.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $29.00: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: RSI 58 mid-range, Bollinger mid-band. Prior stop was $27.01. Score 5.1/10, moderate confidence.
Take-profit target: $42.96 (+47.9% upside). Prior stop was $27.01. Stop-loss: $27.01.
Concentration risk — Product: lorundrostat; Quality below floor (1.4 < 4.0); Value-trap signals (2/5): Margin compression (op margin -11.0%), High leverage (D/E 1.8).
Mineralys Therapeutics, Inc. trades at a P/E of N/A (forward -14.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
15 analysts cover MLYS with a consensus score of 4.2/5. Average price target: $49.
What does Mineralys Therapeutics, Inc. do?Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone...
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor for uncontrolled/resistant hypertension and related cardiorenal conditions. An NDA was submitted December 2025 with a PDUFA date of December 22, 2026; the company has no approved products and no revenue to date.